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Synovial fluid pharmacokinetics of tulathromycin, gamithromycin and
florfenicol after a single subcutaneous dose in cattle
Abstract
Background
Deep digital septic conditions represent some of the most refractory causes of severe lameness in cattle. The
objective of this study was to determine the distribution of tulathromycin, gamithromycin and florfenicol into
the synovial fluid of the metatarsophalangeal (MTP) joint of cattle after single subcutaneous administration of
drug to evaluate the potential usefulness of these single-dose, long-acting antimicrobials for treating bacterial
infections of the joints in cattle.
Results
Twelve cross-bred beef cows were randomly assigned to one of the drugs. Following subcutaneous
administration, arthrocentesis of the left metatarsophalangeal joint was performed at various time points up to
240 hours post-injection, and samples were analyzed for drug concentration. In synovial fluid, florfenicol
pharmacokinetic parameters estimates were: mean Tmax 7 +/− 2 hours, mean t½ 64.9 +/− 20.1 hours and
mean AUC0-inf 154.0 +/− 26.2 ug*h/mL. Gamithromycin synovial fluid pharmacokinetic parameters
estimates were: mean Tmax 8 hours, mean t½ 77.9 +/− 30.0 hours, and AUC0-inf 6.5 +/− 2.9 ug*h/mL.
Tulathromycin pharmacokinetic parameters estimates in synovial fluid were: Tmax 19 +/− 10 hours, t½ 109
+/− 53.9 hours, and AUC0-inf 57.6 +/− 28.2 ug h/mL.
Conclusions
In conclusion, synovial fluid concentrations of all three antimicrobials were higher for a longer duration than
that of previously reported plasma values. Although clinical data are needed to confirm microbiological
efficacy, florfenicol achieved a synovial fluid concentration greater than the MIC90 for F. necrophorum for at
least 6 days.
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Abstract
Background: Deep digital septic conditions represent some of the most refractory causes of severe lameness in
cattle. The objective of this study was to determine the distribution of tulathromycin, gamithromycin and florfenicol
into the synovial fluid of the metatarsophalangeal (MTP) joint of cattle after single subcutaneous administration of
drug to evaluate the potential usefulness of these single-dose, long-acting antimicrobials for treating bacterial infections
of the joints in cattle.
Results: Twelve cross-bred beef cows were randomly assigned to one of the drugs. Following subcutaneous
administration, arthrocentesis of the left metatarsophalangeal joint was performed at various time points up to 240 hours
post-injection, and samples were analyzed for drug concentration. In synovial fluid, florfenicol pharmacokinetic
parameters estimates were: mean Tmax 7 +/− 2 hours, mean t½ 64.9 +/− 20.1 hours and mean AUC0-inf 154.0 +/−
26.2 ug*h/mL. Gamithromycin synovial fluid pharmacokinetic parameters estimates were: mean Tmax 8 hours,
mean t½ 77.9 +/− 30.0 hours, and AUC0-inf 6.5 +/− 2.9 ug*h/mL. Tulathromycin pharmacokinetic parameters estimates
in synovial fluid were: Tmax 19 +/− 10 hours, t½ 109 +/− 53.9 hours, and AUC0-inf 57.6 +/− 28.2 ug h/mL.
Conclusions: In conclusion, synovial fluid concentrations of all three antimicrobials were higher for a longer duration
than that of previously reported plasma values. Although clinical data are needed to confirm microbiological efficacy,
florfenicol achieved a synovial fluid concentration greater than the MIC90 for F. necrophorum for at least 6 days.
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Background
Lameness is an important cause of production loss and
culling in all classes of cattle, making it a significant
economic and welfare concern. In a survey of beef cattle
operations in the US, 31.6% of herds with greater than
200 cows reported selling cattle due to lameness [1],
while 8.4% of death losses of breeding cattle were due to
lameness or injury [2], making it the second most com-
mon single identifiable cause of death. Deep digital sep-
tic conditions represent some of the most refractory
conditions causing severe lameness. In a recent report,
septic arthritis, tenosynovitis and pedal osteitis repre-
sented 15.2% of all beef cattle lameness cases presented
to a veterinary teaching hospital [3].
Medical therapy alone is rarely associated with suc-
cessful resolution of deep septic conditions of the digit,
and medical therapy is more often used in combination
with surgical approaches, including digit amputation or
joint resection. Even when medical therapy is contem-
plated, there are currently no antimicrobials approved
for the treatment of deep limb sepsis in cattle in the
United States. When used for deep digital sepsis, anti-
microbial drugs are administered by various routes,
including systemic, regional intravenous (IV), and intra-
articular. Perceived concerns over the ability to achieve
sufficient concentrations of drug in the synovial struc-
tures by systemic administration has resulted in in-
creased use of local techniques, designed to provide high
concentration of drug at the site of infection to increase
efficacy. Antimicrobials that exhibit concentration-
dependent bacterial killing are most suited for this type
of therapy, as these techniques allow for injection of
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high concentrations of the agent at the site of infection.
However, prohibitions against extralabel use in the U.S.
or voluntary industry bans preclude the use of the
concentration-dependent aminoglycosides, fluoroqui-
nolones and metronidazole in cattle. Regional IV perfu-
sion of ceftiofur [4], tetracycline [5], cefazolin [6] and
florfenicol [7] has been evaluated in cattle, but these drugs
are considered to depend on time >Minimum Inhibitory
Concentration (MIC) to maximize efficacy, which means
frequent treatment. However, regional IV perfusion in cat-
tle requires chute restraint, placement of a tourniquet, and
daily administration of an antimicrobial drug intraven-
ously in the distal limb. In addition, the cephalosporins
may not be administered via an extralabel route in cattle
in the U.S, precluding regional IV perfusion.
We propose that drugs with a high volume of distribution
should achieve sufficient intra-synovial concentrations by a
more easily accomplished route of administration and
may produce therapeutic concentrations within joints.
Additionally, use of long-acting antimicrobial formula-
tions (that is, longer than 24 hours) would limit the
frequency of animal handling and potential disturbance
of a surgical site. Tulathromycin, gamithromycin and
florfenicol have high volumes of distribution in cattle
[8-10] and are available as long-acting formulations.
They are expected to demonstrate a time-dependent
mode of action, for which the time >MIC for a given
pathogen correlates with efficacy, although the pharma-
codynamic parameter for any long-acting formulation
has not been established. Their spectrum of activity
includes Gram-negative anaerobes common in digital
disease [11], namely Fusobacterium necrophorum, as well
as mycoplasmas that have been implicated in arthritis,
making these reasonable choices for an investigation to
determine whether systemic antimicrobials for deep limb
sepsis and septic arthritis of the distal limb might be
possible. Finally, synovial fluid concentrations have not
been previously assessed with these drugs.
The objective of this study was to determine the distri-
bution of tulathromycin, gamithromycin and florfenicol
into the synovial fluid of the metatarsophalangeal (MTP)
joint of cattle after a single subcutaneous dose of drug to
evaluate the potential usefulness of these drugs for bacter-
ial infections of the joint in cattle. We hypothesized that
tulathromycin, gamithromycin and florfenicol would reach
detectable, therapeutic and sustained concentrations in
synovial fluid following a single parenteral dose.
Methods
Animals
Twelve cross-bred beef cows with ages ranging from 2 to
12 years (mean: 6.4 years) were selected for inclusion in this
study based on apparent health upon evaluation and no
evidence of lameness. Cows were 13–83 days postpartum
(mean: 47.2 days), were lactating, and weighed between
480.5 kg and 823.6 kg (mean: 622 kg). Body condition
scores of cows ranged from 3.5-7/9 (mean: 4.8/9) [12].
Experimental design
Four days prior to the start of each of 4 treatment
periods, three of the 12 cows were selected if they had
already calved (non-random selection). At the study site,
they were housed in a paddock and fed ad libitum
coastal Bermuda grass hay and 2 kg of 20% protein
range cubes per cow twice daily. The 3 cows in each
treatment period were randomly assigned to a treatment
group (tulathromycin, gamithromycin or florfenicol), with
the result that four cows were administered each of the
three drugs over the course of the study.
On the first day for each treatment period (3 cows/
period), cows were weighed on a platform floor scale. Each
cow was then restrained in a hydraulic chute with over-
turning capability. Cows were then overturned and foot re-
straints applied. The region of the lateral aspect of the
metatarsophalangeal (MTP) joint of the left limb was
clipped and surgically prepared. Arthrocentesis was per-
formed using a 20ga, 3.8 cm needle and 1.0 mL synovial
fluid removed (Time 0). A portion of this sample was eval-
uated on a refractometer for total protein concentration,
and the remainder was placed in a storage tube (Falcon,
Tewksbury, MA, USA). A light bandage was placed over
the MTP joint, and the cows were returned to standing.
Synovial fluid samples were stored at −80°C. Each cow was
then administered the assigned antimicrobial subcutane-
ously (SC) in the neck (tulathromycin 2.5 mg/kg (Draxxin,
Pfizer, New York, NY, USA), gamithromycin 6 mg/kg
(Zactran, Merial, Duluth, GA, USA), or florfenicol 40 mg/kg
(Nuflor Gold, Intervet, Summit, NJ, USA)). If the total
dose exceeded 10 mL, multiple injection sites were
used. Additional 0.5 mL synovial fluid samples were
collected from the MTP joint at 4, 8, 24, 48, 72, 168 and
240 hours post injection, had total protein concentration
determined, and were stored at −80°C until completion of
the study for determination of drug concentration. Cattle
were monitored twice daily for demeanor, appetite, lame-
ness score (1-5/5; 1 – normal, 5 – severely lame) [13], and
swelling or drainage from the arthrocentesis site. Each
three-cow treatment cycle was repeated four times,
resulting in 4 cows receiving each treatment drug. Indi-
vidual records were maintained for each cow to ensure
post-treatment meat withdrawal times were followed.
Procedures used in this study were approved by the
Texas A&M University Institutional Animal Care and Use
Committee.
Laboratory analysis
Stored synovial fluid samples were analyzed at the Iowa
State University Pharmacology Analytical Support Team
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(PhAST). Synovial fluid concentrations of florfenicol,
gamithromycin and tulathromycin were measured with
high-pressure liquid chromatography–tandem mass
spectrometry utilizing a LTQ ion trap mass spectrom-
eter (Thermo Scientific, San Jose, CA, USA) coupled to
an Agilent 1100 series pump and Autosampler (Agilent
Technologies, Santa Clara, CA, USA). Synovial fluid sam-
ples or synovial fluid standards were prepared as follows:
Briefly, frozen samples or standards were thawed at room
temperature. A 200 μL synovial fluid sample was diluted
with 0.5 mL of ultrapure water and 0.5 mL of ammonium
acetate buffer, pH 4.5. 100 ng and 50 ng of thiamphenicol
and roxithromycin, respectively, were added to each tube
as internal standards and vigorously mixed by vortex. The
samples were centrifuged at 2000 rpm for 20 minutes to
pellet solids. The entire diluted supernatant was applied to
a solid phase extraction (SPE) cartridge, Strata X-C 33
Polymeric Strong Cation (100 mg/3 mL, Phenomenex,
Torrance, CA, USA) which was preconditioned prior with
methanol (1 mL), equilibrated with water (1 mL), followed
by ammonium acetate buffer, pH 4.5 (1 mL) utilizing grav-
ity for filtration. The sample was subsequently washed
with ultrapure water (1 mL), followed by 5% methanol in
water (v/v) (1 mL). The SPE cartridges were dried under
flow of nitrogen for 5 minutes. Florfenicol (and thiamphe-
nicol) was eluted with 2 fractions of 1 mL portions of
70:30 acetonitrile: methanol into a glass test tube. The
SPE cartridges were dried a second time under flow of
nitrogen for 5 minutes. Macrolides were eluted from the
same column with 2 fractions of a 1 mL 5% ammonium
hydroxide in 70:30 acetonitrile: methanol and collected in
the same tube as previously described. Samples were evap-
orated to dryness at 48°C under a stream of nitrogen,
reconstituted with 100 μL 25% (v/v) acetonitrile in water.
An additional 50 μL of ultrapure water was added, and the
entire 150 μL sample was transferred into an injection vial
for LC-MS/MS analysis with the injection volume set to
20 μL. The mobile phases consisted of A: 0.1% formic acid
in water and B: 0.1% formic acid in acetonitrile at a flow
rate of 0.27 mL/min. The mobile phase began at 10% B
with a linear gradient to 95% B at 7 minutes, which was
maintained for 2 minutes, followed by re-equilibration to
10% B. Separation was achieved with an ACE3 C18
column (150 mm × 2.1 mm, 3 μm particles, Advanced
Chromatography Technologies, LTD (MacMod, Chadds
Ford, PA, USA) maintained at 40°C.
Florfenicol eluted at 6.03 minutes, gamithromycin eluted
at 5.64 minutes, tulathromycin eluted at 4.79 minutes,
roxithromycin eluted at 6.75 minutes, and thiamphenicol
eluted at 5.10 minutes. Three SRM transitions were moni-
tored for all target analytes. The quantifying ions for
florfenicol were 218.89, 335.94, and 357.25 m/z. The
quantifying ions for gamithromycin were 462.44, 601.50,
and 619.47 m/z. The quantifying ions for tulathromycin
were 230.96, 251.14, and 289.36 m/z. The quantifying ions
for internal standards roxithromycin and thiamphenicol
were 522.34, 558.22, and 679.35 m/z and 227.10, 290.05,
and 282.00 m/z, respectively. Synovial fluid concentration
of target analytes in unknown samples were calculated
by the Xcalibur software based on the calibration curve.
Results were then viewed in the Quan Browser portion
of the Xcalibur software. The standard curve deter-
mined using bovine synovial fluid ranged 1 to 1000 ng/mL
for florfenicol and 1 to 5000 ng/mL for the macrolides
and was accepted when the correlation coefficient
exceeded 0.99 and measured values were within 15% of
the actual values. Sample concentrations not bracketed
by range of the standard curve were repeated using a
lesser volume of synovial fluid and final concentrations
were back-calculated using the appropriate dilution
factor dependent on the volume of synovial fluid ana-
lyzed. The inter-assay CV for mid and high range con-
trols (100 ng/mL and 500 ng/mL from the calibration
curve) were 3.1 for florfenicol, 5.7 for gamithromycin,
and 4.3 for tulathromycin. There was insufficient
volume of unknown samples for duplicate runs, and
intra-assay CV was not determined.
Noncompartmental analysis was performed using in-
dustry standard software (WinNonLin 6.3, Pharsight) to
estimate the pharmacokinetic parameters in synovial
fluid for each individual animal. The following parame-
ters were estimated for each animal: time of peak serum
drug concentration (Tmax), peak drug concentration
(Cmax), apparent elimination half-life (t1/2, calculated as
ln(2)/λz, λz being the first order rate constant associated
with the terminal portion of the time-concentration
curve as estimated by linear regression of time vs. log
concentration), area under the time-concentration curve
from time zero to the last observed concentration
(AUC0-obs, calculated by the linear trapezoidal rule), area
under the time-concentration curve from time zero
extrapolated to infinity (AUC0-inf, calculated by adding
the last observed concentration divided by λz to the
AUC0-obs), area under the moment curve from time zero
to last observed concentration (AUMC0-obs), area under
the moment curve from time zero extrapolated to infin-
ity (AUMC0-inf ), mean resident time estimated using
time zero to last observed concentrations (MRT0-obs,
calculated as AUMC0-obs/AUC0-obs), and mean residence
time estimated using time zero to infinity (MRT0-inf,
calculated as AUMC0-inf/AUC0-inf ). Mean parameters for
each drug were then calculated from individual animal
estimates.
Results
All synovial fluid samples were successfully collected as
scheduled (see Figures 1, 2 and 3 for synovial fluid concen-
trations). Cows remained apparently healthy throughout
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the study as indicated by normal attitude and appetite.
No cow was scored with a lameness score greater than 1
(normal) at any point in the study. Mild swelling was
noted in some cows at the site of arthrocentesis; this
swelling never interfered with sampling nor was painful
to pressure or produced drainage. Total protein levels
were measured on all synovial fluid samples and ranged
from 0.1-1.6 g/dL (mean: 0.52 g/dL).
Mean synovial fluid pharmacokinetic parameters
for florfenicol, gamithromycin and tulathromycin were
calculated (Table 1).
Discussion
The objective of our study was to demonstrate that
potentially effective concentrations of 3 antimicrobial
drugs are achieved in synovial fluid after subcutaneous
administration of a single dose of long-acting time-
dependent drugs, so that logistically challenging methods
of drug administration such as regional IV infusion can be
avoided. Our sampling strategy focused on determining
concentrations in the elimination phase of drug disposition,
because we were mainly interested in demonstrating overall
drug exposure and elimination rate to compare with previ-
ously described plasma disposition of the drugs [9,14-16].
Characterizing the rate of distribution of drugs into the
joint space was a low priority, so we purposely did not
collect many samples in the early hours after drug
administration but did sample up to 240 hours. We chose
not to evaluate comparative plasma concentrations in the
present study due to financial constraints, and because pub-
lished data are available. This sampling strategy therefore
might have resulted in inaccurate estimates of Cmax. Pub-
lished mean plasma Cmax estimate for florfenicol was 5.9
mcg/mL [17], approximately twice our estimate of 2.7 mcg/
ml. For gamithromycin, Cmax has been estimated to be 0.75
mcg/mL [9], significantly higher than our estimate of 0.14
mcg/mL. And the Cmax estimate for tulathromycin was
0.28 mcg/mL [16] in one study, which is lower than our
estimate of 0.79 mcg/ml. However, because we had a lim-
ited number of samples in the time range of the reported
plasma Tmax of all 3 drugs (5 hrs for florfenicol [17], 8 hrs
for gamithromycin [9], 3 hrs for tulathromycin [16]), and
Figure 1 Florfenicol concentration in synovial fluid. Mean synovial fluid concentrations of florfenicol (mcg/mL) after single SC injection of
40 mg/kg in 4 adult beef cows. The x-axis represents hours post administration.
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because we expect drug distribution into the joint space to
not be immediate, these differences are probably of little
significance clinically.
More important are the comparisons between plasma
t1/2 and synovial t1/2 as well as between the time synovial
concentrations remain above MIC of target organisms as
compared to plasma concentrations. We assumed that
the appropriate pharmacodynamic parameter was time >
MIC, but pharmacodynamic parameters for long-acting
formulations or for macrolides have not been well charac-
terized in the literature. T1/2 of florfenicol in synovial fluid
was estimated to be approximately 65 hrs, compared to
reported plasma t1/2 of 38 hrs [17]. T1/2 of gamithromy-
cin in synovial fluid was estimated to be 78 hrs vs.
51 hrs in plasma as previously reported [9]. Finally, t1/2
of tulathromycin in synovial fluid was estimated in the
present study to be 109 hrs, as compared to the
published plasma t1/2 of 64 hrs [16]. Therefore, it ap-
pears that drug elimination from synovial fluid is slower
than from plasma due to delayed presentation to the or-
gans of elimination, a potential advantage for medical
therapy.
Equally important to compare is the amount of time
that synovial fluid concentrations remained above a par-
ticular concentration, since this is likely to be predictive
of efficacy. Recognizing that a direct comparison be-
tween pathogen MIC and synovial fluid concentration is
not defensible in the absence of supportive clinical data,
a qualitative comparison is helpful in suggesting the
potential for efficacy. Synovial concentrations of florfeni-
col in the present study remained above 0.5 mcg/mL
for approximately 72 hours, which is similar to the
previously reported plasma concentrations. Synovial
concentrations of gamithromycin in the present study
compared favorably with previously reported plasma
concentrations: synovial concentrations were 0.02 mcg/mL
at 72 hrs, as compared to 0.026 mcg/mL previously
reported. Finally, synovial concentration of tulathromy-
cin in the present study averaged 0.078 mcg/mL at
168 hrs, whereas previously reported estimates (from
visual examination of graphical data) were between 0.01
and 0.02 mcg/mL.
MICs for several target pathogens for these 3 drugs have
been reported: Synovial fluid concentrations of florfenicol
Figure 2 Gamithromycin concentration in synovial fluid. Mean synovial fluid concentrations of gamithromycin (mcg/mL) after single SC
injection of 6 mg/kg in 4 adult beef cows. The x-axis represents hours post administration.
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Figure 3 Tulathromycin concentration in synovial fluid. Mean synovial fluid concentrations of tulathromycin (mcg/mL) after single SC injection of
2.5 mg/kg in 4 adult beef cows. The x-axis represents hours post administration.
Table 1 Synovial fluid pharmacokinetic parameters
Florfenicol Gamithromycin Tulathromycin
Mean SD Mean SD Mean SD
Cmax mcg/mL 2.71 0.93 0.14 0.11 0.79 0.57
Tmax hr 7 2 8 0 19 10
λz /hr 0.0115 0.0035 0.0099 0.0038 0.0077 0.0038
t½λz hr 64.9 20.1 77.9 30.0 109.0 53.9
AUClast mcg*hr/mL 142.0 17.5 6.2 2.8 49.7 29.1
AUC0-inf mcg*hr/mL 154.0 26.2 6.5 2.9 57.6 28.2
AUC % Extrap 7.1 6.3 6.2 2.8 18.1 12.1
AUMC0-obs mcg*hr
2/mL 7623 2577 331 122 3323 1577
AUMC0-inf mcg*hr
2/mL 11860 7054 469 124 6490 1311
MRT0-obs hr 53.5 15.4 55.9 14.2 71.7 14.4
MRT0-inf hr 74.1 32.9 75.2 12.3 136.5 65.0
Tmax: time of peak serum drug concentration; Cmax: peak drug concentration; t1/2: apparent elimination half-life calculated as ln(2)/λz, λz being the first order rate
constant associated with the terminal portion of the time-concentration curve; AUC0-obs: area under the time-concentration curve from time zero to the last
observed concentration; AUC0-inf: area under the time-concentration curve from time zero extrapolated to infinity; AUMC0-obs: area under the moment curve from
time zero to the last observed concentration; AUMC0-inf: area under the moment curve from time zero extrapolated to infinity; MRT0-obs: Mean Resident Time
calculated as AUMC0-obs /AUC0-obs; MRT0-inf: Mean Residence Time calculated as AUMC0-inf /AUC0-inf.
Mean pharmacokinetic parameters in synovial fluid estimated via noncompartmental analysis after SC administration of florfenicol (40 mg/kg), gamithromycin
(6 mg/kg), and tulathromycin (2.5 mg/kg) (n = 4/group).
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in the present study would be expected to be above
Fusobacterium necrophorum and Bacteroides melanino-
genicus MIC (MIC90: 0.25 mcg/mL) for at least 6 days,
but not above reported MICs for Trueperella pyogenes
(MIC90: 16 mcg/mL [18]), although these were uterine
isolates. Susceptibility data related to gamithromycin and
Gram-negative anaerobic isolates likely to be responsible
for digital sepsis are not available, so predictions cannot be
made for this drug. Synovial fluid concentrations of tula-
thromycin do not appear to remain above the reported
MIC50 of Fusobacterium necrophorum (2 mcg/mL); how-
ever, tulathromycin is approved for use in the treatment of
footrot, and the plasma concentrations also do not reach
these concentrations, so the PK/PD relationship is likely
more complicated than a simple comparison of concentra-
tion to MIC. One important caveat to these comparisons
of pharmacokinetic values to published data on florfenicol
and tulathromycin is that there have been two commer-
cially available florfenicol preparations (Nuflor, Schering
Plough, Summit, NJ, USA; Nuflor Gold, Intervet, Roseland,
NJ, USA) , and one study of tulathromycin was performed
using prototype formulations [15].
A question might arise about the impact of sample
collection on inflammation in the joint and its effects on
drug concentrations. A previous study [7] used indwell-
ing catheters to facilitate sample collection to evaluate
synovial fluid pharmacokinetics after regional perfusion
in the metatarsophalangeal joint. Synovial fluid samples
for this project, however, were readily obtained with
needle arthrocentesis at each time point. This technique
potentially minimized inflammation in the joint by
eliminating the use of an indwelling foreign body for
240 hours. While total protein concentration of synovial
fluid as measured on a refractometer is an imperfect
indicator of inflammation, the values obtained at each
time point fell well below medial total protein levels seen
in cattle with various forms of noninfectious joint
disease [19]. This, combined with no clinical evidence of
inflammation (swelling, drainage, lameness) in any study
joint, provides an indication that this procedure is both
effective at obtaining sufficient sample for drug analysis
and minimizing inflammatory response. Systemic admin-
istration of antimicrobial drugs may also help prevent
septicemia of the digital vasculature, which has been
reported after regional IV perfusion of lidocaine when
digital sepsis was present [20].
No products used in this study are approved for use in
lactating dairy cattle and their use may only be advo-
cated in beef cattle and non-lactating dairy cattle. Prod-
ucts including ampicillin, ceftiofur and oxytetracycline
make more appropriate choices for dairy cattle, but need
to be evaluated for their synovial fluid pharmacokinetics
in adult cattle. Oxytetracycline concentrations in syn-
ovial fluid have been evaluated after IM injection in
healthy calves [21,22], and IV administration in calves
with experimentally-induced synovitis [23], but these
drugs were not included in the present study.
Conclusions
In conclusion, synovial fluid concentrations of all three
drugs were higher for a longer duration than that of pre-
viously reported plasma values. Although florfenicol
achieved a synovial fluid concentration greater than the
MIC90 for F. necrophorum for at least 6 days, clinical
data are needed to confirm microbiological efficacy.
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